Schedule a Call Back
India set to capture 8-10% of CDMO outsourcing by 2033: McKinsey Report
Industry News- Oct 22,24
The global CDMO market, currently valued at $224 billion, is forecasted to reach $465 billion by 2032, McKinsey’s analysis revealed.
India is projected to account for 8-10% of the global outsourcing work to Contract Development and Manufacturing Organizations (CDMOs) by 2033, according to a report by McKinsey & Company. The shift in outsourcing trends from Europe and the U.S. to Asia is expected to make India and South Korea emerging powerhouses in the CRDMO (Contract Research, Development & Manufacturing Organisation) industry over the next decade.
The global CDMO market, currently valued at $224 billion, is forecasted to reach $465 billion by 2032, McKinsey’s analysis revealed. A significant portion of this growth is being driven by geopolitical developments, with many Indian CRDMOs expecting 20-40% of their new business to arise from these global shifts.
Anirudh Roy Popli, Partner, McKinsey & Company, emphasised that biopharmaceutical companies are increasingly recognising the value Indian CDMOs offer. "With a strong focus on value and innovation, Indian CDMOs are well-positioned to shape the future of healthcare,” he said.
Prem Pavoor, Senior Partner and Head of India & India Healthcare Investments, Eight Roads Ventures, highlighted the opportunities created by shifting geopolitical dynamics and impending legislation. He noted that leading Indian bio-pharma firms are receiving more requests for proposals from U.S. customers. “Although some customers are adopting a wait-and-watch approach, they are clearly looking to diversify their outsourcing footprint amidst global uncertainties,” Pavoor added.
While this shift presents a tremendous opportunity for India, Pavoor cautioned that Indian CDMOs must invest in the right infrastructure and services to handle the surge in demand. "Meeting these expectations will be essential for capitalising on the industry’s evolving needs," he said.
With these trends in motion, India’s CDMO sector stands poised to become a critical player in the global pharmaceutical supply chain, particularly as companies seek to diversify beyond traditional markets.
(ET)
Related Stories
Process Equipment
Pharma units granted 12-month extension for Schedule M compliance
The extension provides time for MSMEs to secure financing and implement the required changes.
Read moreProcess Equipment
Lupin’s ESG score rises to 76 in S&P Global ESG Ratings
A strong sustainability framework is at the heart of Lupin’s strategy and the company has integrated it in all its business operations.
Read moreProcess Equipment
Trump 2.0 may boost Indian pharma opportunities
Experts highlight that higher tariffs on Chinese goods might enable Indian firms to fill supply gaps in the US generic drug market, a critical region that accounts for 30% of Indian pharma sales and..
Read moreRelated Products
Programmable Controllers - Pcd-33a Series
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Pro-Med Instruments (P) Ltd offers a wide range of programmable controllers - PCD-33A Series.
Gasket Graphite Powder
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Arihant Packing & Gasket Company offers a wide range of gasket graphite powder.
Asahi Kasei expands 3D printing filament sales in North America
CHEMICAL PROCESS, FOOD/PHARMA EQUIPMENT & ANALYTICAL INSTRUMENTS
Asahi Kasei, a leading resin and compounding technology provider, has initiated the sales of 3D printing (3DP) filaments in North America through Asahi Kasei Plastics North America (APNA). The soft la Read more
latest News
Subscribe to iNoW
For Industry News on WhatsApp, Give a Miss Call on: +91 84228 74016
